4,295 reports of this reaction
3.6% of all ENZALUTAMIDE reports
#4 most reported adverse reaction
PROSTATIC SPECIFIC ANTIGEN INCREASED is the #4 most commonly reported adverse reaction for ENZALUTAMIDE, manufactured by Astellas Pharma US, Inc.. There are 4,295 FDA adverse event reports linking ENZALUTAMIDE to PROSTATIC SPECIFIC ANTIGEN INCREASED. This represents approximately 3.6% of all 117,902 adverse event reports for this drug.
Patients taking ENZALUTAMIDE who experience prostatic specific antigen increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATIC SPECIFIC ANTIGEN INCREASED is moderately reported among ENZALUTAMIDE users, representing a notable but not dominant share of adverse events.
In addition to prostatic specific antigen increased, the following adverse reactions have been reported for ENZALUTAMIDE:
The following drugs have also been linked to prostatic specific antigen increased in FDA adverse event reports:
PROSTATIC SPECIFIC ANTIGEN INCREASED has been reported as an adverse event in 4,295 FDA reports for ENZALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATIC SPECIFIC ANTIGEN INCREASED accounts for approximately 3.6% of all adverse event reports for ENZALUTAMIDE, making it a notable side effect.
If you experience prostatic specific antigen increased while taking ENZALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.